Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01845025 · ClinicalTrials.gov registry record · Phase 4
Study of Safety of Foradil in Patients With Persistent Asthma
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 827
- Enrollment target
NCT01845025 is a Phase 4 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 827 participants.
The verdict
NCT01845025, a Phase 4 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 827 participants
- Enrollment target
Study Summary
The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combination was the same as those taking inhaled fluticasone propionate alone.
Interventions
- DRUG Placebo
- DRUG Fluticasone propionate 250 mcg
- DRUG Formoterol 12 mcg
- DRUG Fluticasone propionate 100 mcg
- DRUG Fluticasone propionate 500 mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 827 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01845025
The ClinicalTrials.gov registry entry for NCT01845025 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 827 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01845025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01845025 about?
NCT01845025 is a clinical study titled "Study of Safety of Foradil in Patients With Persistent Asthma". The purpose of this study was to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in adolescents and adults (12 years of age and older) taking inhaled formoterol fumarate/fluticasone propionate combinati...
What is the current status of trial NCT01845025?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 827 participants. The study started on 2013-05. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01845025?
The interventions under investigation include: Placebo (DRUG), Fluticasone propionate 250 mcg (DRUG), Formoterol 12 mcg (DRUG), Fluticasone propionate 100 mcg (DRUG), Fluticasone propionate 500 mcg (DRUG).
Who is sponsoring clinical trial NCT01845025?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.